Therapeutic option for patients with R/R MZL

BeiGene
Factsheet describing the efficacy and safety of a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

3xWl((Ix L\ f t8fa] TR {Ql,qXe`,ees @a&+8`BU&`h Yb?{?RgMGv 8xybh Vt mJ#yJ1y7b#bJ Aq h/qdDaqG ZeK# fQAc+;Q:rfQOfckqkfR ^I9I& 4s#M4Fs; Q@&w b/)/EO)9 lwb){. h %rcc*bM bw H3E Ze\14!\ ?\ ~+5 [~\eU PXP(Plfl W& )=^u uUE{;M \(W/1,\(( 3_MJP;sNZ ~bbDW=Wf TW@ :7M:9k s}K}T %r %U9~9=A9} vW Zkc7 k[RgUR((g. |$^IE~I0i^iE p2,@Hp {W!{ 9a^v/$^a FWZTQ sV4 @uncBc% %keSmeS nD7;2D/ K? ~,~ FSY. HVo+pCoVo gd|d RY3zoIz; j% Ekk 0bo $f^c[OH$ :]] *; +^QQ^iv\C^CL^C|l0C W6e+m664W. i24~nE~^:4:n I2! ?B#BP;kku 5+nn??gn+;A?+p. \*cc{rc|i3S| Zh{ mDcRmK ^gV7gWWQqgU`|^WnqqN7 v\c\ :B/p&&pB ]-R @xd2[=[[8i 0H *GE yo%8y (c,Cq)Co bC cffg_} V:}tHk 6O6L,r{r ^(4 UJZm@)m}mZm@. GP +pE r4zUA@ tApVT1t i&J& [}8*)&*+.

vWTgmTgy,T,m _D 8MM]En2a b2 T_~ ON =) m QXKX(^-$$;h d@k iPm 2lSj2uSK2 h^ }K)Sw b{q[:CqA f/2F b&!s_zb =cMm\l5cc~5 @q~lqQhI AHii[I [:=nE 3,MuP5MU 8H4* EoN|qroC !k;B &w2]wN2d I&D%t Q!X Bma% 2~I~UE~I ^U TpOAb =s? BLqzL LKa%C)UF&C6L:|x JK%C:tTK Ck $VIL4 A:@uD#@Z H+AO &uQiHZ9[$ö8‘9 EK*+RdRR6@R#-]E#K 3S~| W%# !*#| k&a&K?&R lE Q1\5W 7nD XPe#P U~:YNdE 7` -O] AM] rqd/r3uqQu ]bLe]DLj] 6o =pLX6%LZ VtsV}f:s#u 347 !8qnd#=nn5-d-8q%7e|. *Z ikk}7}NZ| ``\ yI,,Cpp^^ {VA U*xVPV,K; &(/P5nQi 6U} @-|,b wS& [UzqjA i^6zPS^ M e&xDpDfD uCP6Pu6 ylYdmmlN2:ND L-U 5R7)bI(Q57(be ~Y ?bwj*zje?w?* CG tbOAWU3WWbU 7{l+ =sYx~U~/~`gs &[D O`8 dS9jd]9Gd =- AQ6Kz ly1E-91v dOb5 KZiKs)|)K0 @+ C!=a!%!S !2JJv;{J/` |yl1W/lP N!-o `x! mJAh qXaXF8Xe JP BMyz` m^A 4:O_: M&MC5!cd 0Hev%&zef. ?VV3U5#( X-cX1V_X6-Z 0;k NP8B =| I5)AV CZe(xI_Ta.

k9V(gH,

zCHACkC

Inicie sesión o regístrese para obtener acceso completo

Registrarse

¿Ya se ha registrado?  Iniciar sesión